Grace Lynn Su, MD
Ophthalmology · Fontana
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Southern California Permanente Medical Group · 11,250 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Su’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A185652 · Current
Licensed to practise in California · since 2023 · expires 2027-04-30 · Lewis Katz School of Medicine at Temple University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MDRE.ML.61064784Physician And Surgeon Residency Limited License · since 2020 · expires 2023-07-31Matched by name, not licence number; check the name before relying on it.ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Original Medicare doctor bills
$8,958
Medicare paid this office $8,958 for 66 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Transplantation of outer layer of corneal tissue | 18 | $3,006 | $158 |
| Short return visit (20+ min) | 12 | $871 | $51 |
Who their Medicare patients are
66 Original Medicare patients in 2024. Average age 77 · Women 50% · Also on Medicaid 32% · Health risk score 1.72. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Coronary heart disease 36% · Diabetes 35% · Chronic kidney disease 32% · Atrial fibrillation 27% · Depression 26% · Heart failure 24%.
The office billed $81,329, Medicare allowed $11,934 and paid $8,958; for 86 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 66 | 86 | 77 | 1.72 | $81,329 | $8,958 |
| 2023 | 46 | 62 | 74 | 1.80 | $54,751 | $6,469 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Medicaid work
$14,053 in 2024
Medicaid paid $14,053 for 284 billed services this clinician did in 2024, up to 39 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 135 | $8,213 |
| Short return visit (20+ min) | 107 | $4,821 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 29 | $810 |
| COMPUTERIZED CORNEAL TOPOGRAPHY UNI/BI W/I&R | 13 | $209 |
| 2024 | 284 | 4 | 39 | $14,053 |
| 2023 | 74 | 1 | 20 | $4,208 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 74 | $4,208 |
Drugs they prescribed that Part D paid
$451,815
Pharmacies billed $451,815 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
555 generic and 634 brand-name prescriptions · $451,815 in drug cost · 38 antibiotic prescriptions to 19 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xiidra | 73 | $72,773 | $997 |
| Restasis | 71 | $49,571 | $698 |
| Miebo | 34 | $30,102 | $885 |
| Cyclosporine | 54 | $20,867 | $386 |
| Prednisolone Acetate | 306 | $11,171 | $37 |
See all 21 drugs
| Xiidra | 73 | $72,773 | $997 |
| Restasis | 71 | $49,571 | $698 |
| Miebo | 34 | $30,102 | $885 |
| Cyclosporine | 54 | $20,867 | $386 |
| Prednisolone Acetate | 306 | $11,171 | $37 |
| Ilevro | 12 | $4,187 | $349 |
| Moxifloxacin | 180 | $3,804 | $21 |
| Combigan | 14 | $2,653 | $189 |
| Loteprednol Etabonate | 13 | $1,919 | $148 |
| Valacyclovir | 31 | $1,869 | $60 |
| Fluorometholone | 21 | $1,757 | $84 |
| Dorzolamide-Timolol | 47 | $842 | $18 |
| Brimonidine | 28 | $619 | $22 |
| Ketorolac Tromethamine | 38 | $395 | $10 |
| Doxycycline Monohydrate | 15 | $395 | $26 |
| Acyclovir | 17 | $361 | $21 |
| Timolol Maleate | 16 | $356 | $22 |
| Latanoprost | 23 | $350 | $15 |
| Doxycycline Hyclate | 21 | $320 | $15 |
| Erythromycin | 20 | $219 | $11 |
| Ofloxacin | 17 | $130 | $8 |
Year by year
| 2024 | 1,189 | 393 | None | 53% | $451,815 |
| 2023 | 480 | 215 | None | 50% | $252,817 |
| 2022 | 438 | 130 | 0% (0) | 38% | $56,293 |
| 2021 | 276 | 122 | None | 33% | $26,597 |
| 2020 | 31 | 15 | None | 52% | $1,976 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Restasis | 43 | $36,813 | $856 |
| Cyclosporine | 12 | $7,314 | $609 |
| Prednisolone Acetate | 90 | $2,948 | $33 |
| Moxifloxacin | 76 | $2,612 | $34 |
| Brimonidine | 20 | $1,866 | $93 |
| Latanoprost | 34 | $923 | $27 |
| Dorzolamide-Timolol | 22 | $740 | $34 |
| Ketorolac Tromethamine | 23 | $532 | $23 |
2022: 11 drugs
| Restasis | 30 | $22,869 | $762 |
| Rhopressa | 16 | $9,143 | $571 |
| Latanoprost | 98 | $2,919 | $30 |
| Prednisolone Acetate | 37 | $2,677 | $72 |
| Dorzolamide-Timolol | 43 | $1,349 | $31 |
| Brimonidine | 33 | $970 | $29 |
| Moxifloxacin | 19 | $825 | $43 |
| Ketorolac Tromethamine | 26 | $764 | $29 |
| Timolol Maleate | 32 | $420 | $13 |
| Ofloxacin | 19 | $278 | $15 |
| Erythromycin | 14 | $265 | $19 |
2021: 7 drugs
| Restasis | 12 | $13,016 | $1,085 |
| Prednisolone Acetate | 40 | $2,689 | $67 |
| Latanoprost | 36 | $1,098 | $31 |
| Brimonidine | 30 | $715 | $24 |
| Dorzolamide-Timolol | 18 | $637 | $35 |
| Ofloxacin | 27 | $434 | $16 |
| Timolol Maleate | 18 | $404 | $22 |
Money from drug and device companies
$135 in 2024
| 2024 | 2 | 3 | None | $135 |
| 2023 | 4 | 22 | $1,000 | $3,038 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| RxSight | Rxsight Contact Lens | $77 | 1 payment
|
| Glaukos | Istent Trabecular Micro-Bypass System Model Is3 | $58 | 2 payments
|
See all 3 published payments
| Glaukos | Meals · 2024-06-09 | Istent Trabecular Micro-Bypass System Model Is3 | $25 |
| Glaukos | Meals · 2024-05-30 | Istent Trabecular Micro-Bypass System Model Is3 | $33 |
| RxSight | Meals · 2024-05-02 | Rxsight Contact Lens | $77 |
See earlier years (2023)
2023: $3,038
| Bausch & Lomb Americas | Stellaris Elite | $2,333 | 10 payments
|
| Johnson & Johnson Surgical Vision | Lipiflow System Activator II (Disposable | $525 | 9 payments
|
| Glaukos | None | $149 | 2 payments
|
| AbbVie | Durysta | $31 | 1 payment
|
Professional record
- NPI
- 1265994933
- Licence
- CA A185652California A185652: Current · expires 2027-04-30Washington MDRE.ML.61064784: Expired
- Trained
- Temple University School of Medicine, 2019
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 4616 Sw 328th Pl, Federal Way, WA, 98023
- NPI first listed
- 2019-04-02
- NPI last updated
- 2024-10-25
- NPI record certified
- 2023-05-04
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.